Reha Technology AG has terminated the strategic
partnership with Hocoma retroactively as of February 17, 2023 with immediate effect.
Olten, Switzerland – Reha Technology AG announces that its strategic partnership with Hocoma has been terminated as of February 17th, 2023. Reha Technology will continue to advance its leading end-effector gait therapy with the G-EO gait trainer and make it available to the market worldwide.
Reha Technology regrets that the partnership could not be continued. The company has decided to terminate the partnership because Hocoma did not comply with its contractual agreements to actively distribute and expand the customer base as agreed. Despite repeated efforts to maintain the partnership, the decision was ultimately made to end the collaboration.
Reha Technology AG will expand its presence as a reliable distributor and service partner in providing the G-EO gait trainer with its unique end-effector gait therapy to the market in a new and strengthened way.
In countless studies, the G-EO has demonstrated clinical evidence in end-effector-based gait therapy compared to conventional therapy. The gait robot uniquely supports functional clinical outcomes in adult and pediatric patients with neurological impairments resulting from stroke, traumatic brain injury, spinal cord injury, infantile cerebral palsy (ICP), Parkinson’s disease, and other neurologically-induced movement disorders. The use of gait trainers in clinics and practices significantly increases the cost-effectiveness and efficiency of gait rehabilitation, relieves therapists of physical work, and leads patients to more effective and targeted self-reliant walking.
Reha’s robotic-assisted therapy devices maximize functional clinical outcomes for adult and pediatric patients with neurological impairments resulting from stroke, traumatic brain and spinal cord injuries, infantile cerebral palsy, Parkinson’s, as well as other neurologic conditions. Reha’s ambition is to improve the quality of life for those who have been injured or disabled by illness or accident.
“We regret that we can no longer continue this strategic partnership, but we are determined to further expand our leading position in end-effector gait therapy with the G-EO,” said Peter Pauli, Chairman of Reha Technology AG. “We believe that end-effector-based gait therapy will have a sustainable, positive impact on patient rehabilitation and quality of life, and we look forward to offering the market an excellent gait robot with the G-EO.”